MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

 

 AZD-7451   

     

Description of AZD7451: AZD7451 is a tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. AZD7451 binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

 

Current developer: AstraZenca.

 

MedKoo Cat#: 205820

Name:  AZD7451

CAS#:  

  

Synonym:  AZD7451; AZD-7451; AZD 7451

  

IUPAC/Chemical name: 

  

  

Chemical structure

Theoretical analysis

 

 

 

 

 

 

  

Availability and price:

 

This agent is not in stock, which may be available through  custom synthesis.

  

 

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

 

 

Highlights of recent research using this agent

  

 

 

References

 

 

 

Contact MedKoo:

Tel: 919-279-0682
Fax: 919-980-4831
Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved